Our India plan is generally for the long run. India will not yield immediate results. In the longer run, India is a good market.
What are your thoughts on investing in biologics, especially as return on investment is not assured in that segment?
It’s true that there’s uncertainty in biologics. However, since we focus on specialised therapies we can afford to concentrate on biologics. We will invest in biologics.